Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Toffoli

Showing results (21-30 of 265) with videos related to

Pageof 27
Sort By:
Pharmacogenomics|November 29, 2011
Research highlights. PI3K/AKT/mTOR inhibitors would require PI3KCA-mutation analysisChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
AIDS (London, England)|May 24, 2013
Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphomaGiuseppe Corona, Emanuela Vaccher, Michele Spina, et al.
Plos One|February 18, 2015
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic studyElena Marangon, Bianca Posocco, Elisa Mazzega, et al.
Therapeutic Drug Monitoring|August 5, 2010
Fast liquid chromatography-tandem mass spectrometry method for routine assessment of irinotecan metabolic phenotypeGiuseppe Corona, Caterina Elia, Bruno Casetta, et al.
Pharmacogenomics|October 20, 2011
Research highlights. MCL1 and FBW7 as new predictive candidate biomarkers of anti-tubulin agentsChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
Pharmacogenomics|November 15, 2012
miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?Eva Dreussi, Paola Biason, Giuseppe Toffoli, et al.
Clinical Pharmacokinetics|May 14, 2004
Pharmacokinetic optimisation of treatment with oral etoposideGiuseppe Toffoli, Giuseppe Corona, Barbara Basso, et al.
Pharmacogenomics|November 29, 2011
Research highlights. Overcoming BRAF resistance to PLX4032 by AKT inhibition in PTEN-deficient melanoma cellsChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
Journal of Cellular Physiology|November 23, 2011
Pharmaco-metabolomics: an emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targetsGiuseppe Corona, Flavio Rizzolio, Antonio Giordano, et al.
Oncotarget|August 1, 2013
pRb controls estrogen receptor alpha protein stability and activityIsabella Caligiuri, Giuseppe Toffoli, Antonio Giordano, et al.
Pageof 27

Showing results (21-30 of 265) with videos related to

Sort By:
Pageof 27
Pharmacogenomics|November 29, 2011
Research highlights. PI3K/AKT/mTOR inhibitors would require PI3KCA-mutation analysisChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
AIDS (London, England)|May 24, 2013
Potential hazard drug-drug interaction between boosted protease inhibitors and vinblastine in HIV patients with Hodgkin's lymphomaGiuseppe Corona, Emanuela Vaccher, Michele Spina, et al.
Plos One|February 18, 2015
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the simultaneous determination of irinotecan and its main metabolites in human plasma and its application in a clinical pharmacokinetic studyElena Marangon, Bianca Posocco, Elisa Mazzega, et al.
Therapeutic Drug Monitoring|August 5, 2010
Fast liquid chromatography-tandem mass spectrometry method for routine assessment of irinotecan metabolic phenotypeGiuseppe Corona, Caterina Elia, Bruno Casetta, et al.
Pharmacogenomics|October 20, 2011
Research highlights. MCL1 and FBW7 as new predictive candidate biomarkers of anti-tubulin agentsChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
Pharmacogenomics|November 15, 2012
miRNA pharmacogenomics: the new frontier for personalized medicine in cancer?Eva Dreussi, Paola Biason, Giuseppe Toffoli, et al.
Clinical Pharmacokinetics|May 14, 2004
Pharmacokinetic optimisation of treatment with oral etoposideGiuseppe Toffoli, Giuseppe Corona, Barbara Basso, et al.
Pharmacogenomics|November 29, 2011
Research highlights. Overcoming BRAF resistance to PLX4032 by AKT inhibition in PTEN-deficient melanoma cellsChiara Lucchetti, Flavio Rizzolio, Matteo Castronovo, et al.
Journal of Cellular Physiology|November 23, 2011
Pharmaco-metabolomics: an emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targetsGiuseppe Corona, Flavio Rizzolio, Antonio Giordano, et al.
Oncotarget|August 1, 2013
pRb controls estrogen receptor alpha protein stability and activityIsabella Caligiuri, Giuseppe Toffoli, Antonio Giordano, et al.
Pageof 27